glp-1 drugs and lupus Association between autoimmune diseases glucagon-like peptide-1 receptor agonists: A real-world evidence study Advances in the treatment of

Tirzepatide population pharmacokinetics and exposure Schneck 19-study pooled popPK (CL/F 0.061 L/h, half-life 5.4 d, accumulation 1.7x, body-weight covariate +22% at 70 kg / -33% at 120 kg)

Pseudoginsengenin DQ exhibits therapeutic effects in cisplatin-induced acute kidney injury via Sirt1/NF-B and caspase signaling pathway without compromising its antitumor activity in mice

As, la regeneracin de los mismos es ms rpida, no se requiere de tanto tiempo de recuperacin, y la posibilidad de sufrir alguna lesin ser ms reducida

Always prioritise evidence-based treatments recommended by your healthcare team

Tirzepatide demonstrated remarkable weight-reducing efficacy in randomized controlled trials such as SURMOUNT-1 and SURMOUNT-2, with mean body-weight reductions ranging from 15 to 22.5% (32, 33)